MYGN
Myriad Genetics, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -3.1% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 966.11K | $4.16M | n/a | n/a |
| Q2 2026 | 84 | -4 | 70.39M | $401.85M | +6 | −11 |
| Q1 2026 | 92 | -3 | 73.19M | $329.45M | +3 | −6 |
| Q4 2025 | 95 | 0 | 80.50M | $495.06M | n/a | n/a |
| Q3 2025 | 19 | 0 | 56.51M | $408.57M | n/a | n/a |
| Q2 2025 | 16 | 0 | 51.45M | $273.22M | +1 | −1 |
| Q1 2025 | 13 | 0 | 25.12M | $222.86M | +1 | −1 |
| Q4 2024 | 13 | -1 | 27.01M | $370.33M | n/a | −1 |
| Q3 2024 | 13 | +3 | 18.94M | $518.67M | +3 | n/a |
| Q2 2024 | 10 | n/a | 22.76M | $556.69M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 7.88M | -14.8% | $56.99M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 2 | State Street Global Advisors ✦ (passive) | 4.98M | +3.5% | $35.98M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | D. E. Shaw & Co. ✦ | 4.56M | +1.1% | $32.96M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 4 | Morgan Stanley ✦ | 3.62M | n/a | $26.15M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 5 | Goldman Sachs Group ✦ | 2.15M | n/a | $15.56M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 6 | Fisher Asset Management ✦ | 1.28M | -1.2% | $9.25M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 7 | JPMorgan Chase ✦ | 1.10M | n/a | $7.99M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 8 | Fidelity (FMR) ✦ | 398.23K | +14.2% | $2.88M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 9 | T. Rowe Price ✦ | 60.27K | +9.2% | $436,000 | 0.0% | ▲ Add | 6 | SEC ↗ |
| 10 | Renaissance Technologies ✦ | 21.67K | -95.2% | $156,703 | 0.0% | ▼ Trim | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 200 holders, 87.60M shares, $371.14M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.